Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
Milrod C, Chorzalska A, Morgan J, Pardo M, Raker C, Ollila T, Lee S, Pelcovits A, Reagan J, McMahon J, Donnelly S, Carmody C, Margolis J, Matasar M, Huntington S, Dubielecka P, Olszewski A. Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma. Blood 2024, 144: 1614-1614. DOI: 10.1182/blood-2024-193023.Peer-Reviewed Original ResearchCD8+ T cellsCD8+ T cell subsetsT cell activationEM CD8+ T cellsB-cell lymphomaT cell subsetsT cellsBsAb therapyComplete responseEffector memoryImmune responseCD8+ T cell activationT cell-engaging therapiesTreatment of B-cell lymphomaCentral memory T cellsT cell activation markersAlternative administration schedulesCD8+T cell activityLow-dose lenalidomidePrior chemotherapy exposureMarginal zone lymphomaT cell exhaustionT-cell engagersAnti-lymphoma activityMemory T cells